Will the FDA Give This Drug the Green Light?

In the following video, Motley Fool health care bureau chief Brenton Flynn discusses an upcoming FDA decision on this Sunday, Feb. 10, on whether to approve Celgene's (NASDAQ: CELG  ) drug pomalidomide, which is used in the treatment of blood cancer multiple myeloma. While there is little doubt that the drug will be approved, Brenton highlights the bigger question at stake here: Considering the competition in this space -- including one of Celgene's own drugs, which may cannibalize sales -- just how big will this drug become?

Should you give Celgene the green light?
With Celgene's broad portfolio of drugs and a strong pipeline to boot, many investors see it as a smarter way to play the biotech investing game. If you're interested in owning the stock, you need to know about the key opportunities and risks facing the company. The Fool's brand new premium report on Celgene takes you through everything you need to know. To claim your copy today, simply click here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2430841, ~/Articles/ArticleHandler.aspx, 9/16/2014 7:46:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement